| Name | Title | Contact Details |
|---|
Axcel Photonics is a Marlborough, MA-based company in the Computers and Electronics sector.
CI Systems Inc is a Simi Valley, CA-based company in the Computers and Electronics sector.
Xeal is a technology-first electric vehicle (EV) charging company operating at the intersection of mobility, real estate, IoT, and energy. We are building the next generation of EV charging solutions to take the market from 1% to 100% mass adoption. We tackle the world`s greatest challenges with disruptive, yet practical solutions for the built environment and future of smart cities. Xeal has been adopted by the nation`s largest real estate companies to electrify thousands of parking spaces.
Palma Ceia SemiDesign (PCS) is a fabless semiconductor company and leading provider of communication semiconductors and IP for next-generation Wi-Fi and cellular applications. With a focus on emerging Wi-Fi and LTE standards, particularly for IoT (Internet of Things), PCS targets the design of ICs for broadband, wireless, medical, and automotive applications. Palma Ceia SemiDesign solutions are differentiated by low power, high performance, and ease of integration. Headquartered in the Cayman Islands, the company has design and sales support centers in Cambridge (United Kingdom), mainland China, Hong Kong, and McKinney, Texas (United States). PCS is soon expanding to provide direct support for Israel, Japan, Korea, and Taiwan.
Xceleron believes that AMS technology and our expertise can get life-changing products (drugs and biobased) quickly and cost-effectively to people who need them. We work with integrity and an open mind and are driven by science and the spirit of collaboration. Founded in 1997 in York, UK, and now headquartered in Germantown, Maryland, Xceleron pioneered human microdose and microtracer techniques using AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I, and Phase II/III clinical trials. Xceleron’s experience is especially valuable because the characteristics of many contemporary small molecules (low solubility, long half-life and disproportionate human metabolites) mean that their early pharmacokinetic and metabolic characterization is critical to the cost-effectiveness of clinical development.